Nanotechnology applied to treatment of mucopolysaccharidoses

References

• Giugliani R. Mucopolysacccharidoses: from understanding to treatment, a century of discoveries. Genet Mol Biol. 2012;35(4):924–931.
   PubMed Web of Science ®Google Scholar
• Baldo G, Giugliani R, Matte U. Gene delivery strategies for the treatment of mucopolysaccharidoses. Expert Opin Drug Deliv. 2014;11(3):449–459.
   PubMed Web of Science ®Google Scholar
• Giugliani R, Federhen A, Rojas MVM, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589–604.
   PubMed Web of Science ®Google Scholar
• Morille M, Passirani C, Vonarbourg A, et al. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24–5):3477–3496.
   PubMed Web of Science ®Google Scholar
• Zorzi GK, Seijo B, Sanchez A. Endogenous polymers as biomaterials for nanoparticulate gene therapy. In: Thakur VK, Thakur MK, editors. Handbook of polymers for pharmaceutical technologies. Hoboken (NJ): John Wiley & Sons, Inc.; 2015. p. 237–259.
   Google Scholar
• Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicol Pathol. 2008;36(1):21–29.
   PubMed Web of Science ®Google Scholar
• Bouchemal K, Briancon S, Perrier E, et al. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm. 2004;280(1–2):241–251.
   PubMed Web of Science ®Google Scholar
• Schuh RS, Bruxel F, Teixeira HF. Physicochemical properties of lecithin-based nanoemulsions obtained by spontaneous emulsification or high-pressure homogenization. Quim Nova. 2014;37:1193–1198.
   Web of Science ®Google Scholar
• Ravi Kumar M, Hellermann G, Lockey RF, et al. Nanoparticle-mediated gene delivery: state of the art. Expert Opin Biol Ther. 2004;4(8):1213–1224.
   PubMed Web of Science ®Google Scholar
• Ditto AJ, Shah PN, Yun YH. Non-viral gene delivery using nanoparticles. Expert Opin Drug Deliv. 2009;6(11):1149–1160.
   PubMed Web of Science ®Google Scholar
• Fraga M, Bruxel F, Diel D, et al. PEGylated cationic nanoemulsions can efficiently bind and transfect pIDUA in a mucopolysaccharidosis type I murine model. J Control Release. 2015;209:37–46.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Boado RJ, et al. Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. Pharm Res. 2008;25(2):400–406.
   PubMed Web of Science ®Google Scholar
• Mayer FQ, Adorne MD, Bender EA, et al. Laronidase-functionalized multiple-wal l lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis Type I. Pharm Res. 2015;32:941–954.
   PubMed Web of Science ®Google Scholar
• Muhlstein A, Gelperina S, Kreuter J. Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI. Pharmazie. 2013;68(7):549–554.
   PubMed Web of Science ®Google Scholar
• Fraga M, De Carvalho TG, Diel D Da S, et al. Cationic nanoemulsions as a gene delivery system: proof of concept in the mucopolysaccharidosis I murine model. J Nanosci Nanotechnol. 2015;15(1):810–816.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.
   PubMed Web of Science ®Google Scholar
• Kwon SM, Nam HY, Nam T, et al. In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier. J Control Release. 2008;128(1):89–97.
   PubMed Web of Science ®Google Scholar
• Rao NM, Gopal V. Cationic lipids for gene delivery in vitro and in vivo. Expert Opin Ther Pat. 2006;16(6):825–844.
   Web of Science ®Google Scholar
• Nordling-David MM, Golomb G. Gene delivery by liposomes. Isr J Chem. 2013;53(9–10, (SI)):737–747.
   Web of Science ®Google Scholar
• Lu C, Stewart DJ, Lee JJ, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012;7(4):e34833.
   PubMed Web of Science ®Google Scholar
• Lavigne MD, Górecki DC. Emerging vectors and targeting methods for nonviral gene therapy. Expert Opin Emerg Drugs. 2006;11(3):541–557.
   PubMedGoogle Scholar
• Bruxel F, Vilela JMC, Andrade MS, et al. Investigation of the structural organization of cationic nanoemulsion/antisense oligonucleotide complexes. Colloids Surf B. 2013;112:530–536.
   PubMed Web of Science ®Google Scholar
• Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim Biophys Acta. 1994;1189(2):195–203.
   PubMed Web of Science ®Google Scholar
• Nam HY, Park JH, Kim K, et al. Lipid-based emulsion system as non-viral gene carriers. Arch Pharm Res. 2009;32(5):639–646.
   PubMed Web of Science ®Google Scholar
• McNeil SE, Perrie Y. Gene delivery using cationic liposomes. Expert Opin Ther Pat. 2006;16(10):1371–1382.
   Web of Science ®Google Scholar
• Verissimo LM, Lima LFA, Egito LCM, et al. Pharmaceutical emulsions: a new approach for gene therapy. J Drug Target. 2010;18(5):333–342.
   PubMed Web of Science ®Google Scholar
• Liu C-H, Yu S-Y. Cationic nanoemulsions as non-viral vectors for plasmid DNA delivery. Colloids Surf B. 2010;79(2):509–515.
   PubMed Web of Science ®Google Scholar
• Romøren K, Thu BJ, Bols NC, et al. Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin. Biochim Biophys Acta - Biomembr. 2004;1663(1):127–134.
   PubMed Web of Science ®Google Scholar
• Bruxel F, Laux M, Wild LB, et al. Nanoemulsões como sistemas de liberação parenteral de fármacos. Quim Nova. 2012;35:1827–1840.
   Web of Science ®Google Scholar
• Wilkinson FL, Sergijenko A, Langford-Smith KJ, et al. Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation. Mol Ther. 2013;21(4):868–876.
   PubMed Web of Science ®Google Scholar
• Gref R, Couvreur P. Nanocapsules: preparation, characterization and therapeutic applications. In: Torchilin VP, editor. Nanoparticulates as drug carriers. London: Imperial College Press; 2006. p. 720.
   Google Scholar
• Kim SH, Jeong JH, Lee SH, et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release. 2006;116(2SPEC. ISS.):123–129.
   PubMed Web of Science ®Google Scholar
• Bhattarai N, Ramay HR, Gunn J, et al. PEG-grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. J Control Release. 2005;103(3):609–624.
   PubMed Web of Science ®Google Scholar
• Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta - Biomembr. 1997;1329(2):345–356.
   PubMed Web of Science ®Google Scholar
• Kim TW, Chung H, Kwon IC, et al. Optimization of lipid composition in cationic emulsion as in vitro and in vivo transfection agents. Pharm Res. 2001;18(1):54–60.
   PubMed Web of Science ®Google Scholar
• Vasir JK, Labhasetwar V. Polymeric nanoparticles for gene delivery. Expert Opin Drug Deliv. 2006;3(3):325–344.
   PubMed Web of Science ®Google Scholar
• Mundargi RC, Babu VR, Rangaswamy V, et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125:193–209.
   PubMed Web of Science ®Google Scholar
• Dziublaa TD, Shuvaeva VV, Honga NK, et al. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials. 2008;29:215–227.
   PubMed Web of Science ®Google Scholar
• Wilson B. Brain targeting PBCA nanoparticles and the blood-brain barrier. Nanomedicine (Lond). 2009;4(5):499–502.
   PubMed Web of Science ®Google Scholar
• Sinha VR, Bansal K, Kaushik R, et al. Poly-ϵ-caprolactone microspheres and nanospheres: an overview. Int J Pharm. 2004;278(1):1–23.
   PubMed Web of Science ®Google Scholar
• Dash TK, Konkimalla VB. Poly-є-caprolactone based formulations for drug delivery and tissue engineering: A review. J Control Release. 2012;158(1):15–33.
   PubMed Web of Science ®Google Scholar
• Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier—Systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B. 2007;59(1):24–34.
   PubMed Web of Science ®Google Scholar
• Sinha VR, Singla AK, Wadhawan S, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 2004;274(1–2):1–33.
   PubMed Web of Science ®Google Scholar
• Matte U, Yogalingam G, Brooks D, et al. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab. 2016;78(1):37–43. doi:10.1016/S1096-7192(02)00200-7.
   Web of Science ®Google Scholar
• Hollak CEM, Wijburg FA. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis. 2014;37(4):587–598.
   PubMed Web of Science ®Google Scholar
• Giugliani R. Newborn screening for lysosomal diseases: current status and potential interface with population medical genetics in Latin America. J Inherit Metab Dis. 2012;35(5):871–877.
   PubMed Web of Science ®Google Scholar
• Lund TC. Hematopoietic stem cell transplant for lysosomal storage diseases. Pediatr Endocrinol Rev. 2013;11(Suppl 1):91–98.
   PubMedGoogle Scholar
• Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21(6):1106–1109.
   PubMed Web of Science ®Google Scholar
• Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome. Mol Genet Metab Reports. 2014;1:184–196.
   PubMedGoogle Scholar
• Araya K, Sakai N, Mohri I, et al. Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation. Mol Genet Metab. 2009;98(3):255–263.
   PubMed Web of Science ®Google Scholar
• Chinen Y, Higa T, Tomatsu S, et al. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Reports. 2014;1:31–41.
   PubMedGoogle Scholar
• Tanjuakio J, Suzuki Y, Patel P, et al. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Mol Genet Metab. 2015;114(2):161–169.
   PubMed Web of Science ®Google Scholar
• Yabe H, Tanaka A, Chinen Y, et al. Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab. 2016;117(2):84–94.
   PubMed Web of Science ®Google Scholar
• Gabrielli O, Clarke LA, Ficcadenti A, et al. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment. BMC Med Genet. 2016;17(1):1–7.
   PubMed Web of Science ®Google Scholar
• Giugliani R, Federhen A, Vairo F, et al. Emerging drugs for the treatment of mucopolysaccharidoses. Expert Opin Emerg Drugs. 2016;21(1):9–26.
   PubMed Web of Science ®Google Scholar
• Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology. 2011;50(5):49–59.
   Web of Science ®Google Scholar
• Giugliani R, Federhen A, Silva A, et al. Emerging treatment options for the mucopolysaccharidoses. Res Reports Endocr Disord. 2012;2:53–64.
   Google Scholar
• Meikle PJ, Fuller M, Hopwood JJ. Lysosomal degradation of heparin and heparan sulfate. In: Garg HG, Linhardt RJ, Hales CA, editors. Chemistry and biology of heparin and heparan sulfate. London: Elsevier Ltd.; 2011. p. 792.
   Google Scholar
• Hawkins-Salsbury JA, Reddy AS, Sands MS. Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts? Hum Mol Genet. 2011;20(1):54–60.
   Web of Science ®Google Scholar
• Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344(3):182–188.
   PubMed Web of Science ®Google Scholar
• Fuller M, Meikle PJ, Hopwood JJ. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology. 2004;14(5):443–450.
   PubMed Web of Science ®Google Scholar
• Ali J, Fazil M, Qumbar M, et al. Colloidal drug delivery system: amplify the ocular delivery. Drug Deliv. 2016;23(3):710–726.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10(4):317–325.
   PubMed Web of Science ®Google Scholar
• Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006;317(3):1246–1253.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhou Q-H, Lu JZ, et al. Pharmacokinetics and brain uptake of a genetically engineered bi-functional fusion antibody targeting the mouse transferrin receptor. Mol Pharm. 2010;7(1):237–244.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhang Y, Zhang Y, et al. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007;96(2):381–391.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Hui EK-W, Lu JZ, et al. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in rhesus monkeys. J Biotechnol. 2009;144(2):135–141.
   PubMed Web of Science ®Google Scholar
• Osborn MJ, McElmurry RT, Peacock B, et al. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol Ther. 2008;16(8):1459–1466.
   PubMed Web of Science ®Google Scholar
• Acosta W, Ayala J, Dolan MC, et al. RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies. Sci Rep. 2015;5:141–144.
   Web of Science ®Google Scholar
• Chen Z-L, Huang M, Wang X-R, et al. Transferrin-modified liposome promotes alpha-mangostin to penetrate the blood-brain barrier. Nanomedicine. 2016;12(2):421–430.
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Bennett W, et al. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab. 2009;98(3):235–242.
   PubMed Web of Science ®Google Scholar
• Friso A, Tomanin R, Salvalaio M, et al. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol. 2010;159(5):1082–1091.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Hui EK-W, Lu JZ, et al. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm. 2011;8(4):1342–1350.
   PubMed Web of Science ®Google Scholar
• Salvalaio M, Rigon L, Belletti D, et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS One. 2016;11(5):e0156452.
   PubMed Web of Science ®Google Scholar
• Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol. 2007;18(1):26–30.
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Alméciga-Díaz CJ, Montaño AM, et al. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab. 2015;114(2):94–109.
   PubMed Web of Science ®Google Scholar
• Grubb JH, Vogler C, Levy B, et al. Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A. 2008;105(7):2616–2621.
   PubMed Web of Science ®Google Scholar
• Rowan DJ, Tomatsu S, Grubb JH, et al. Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Mol Genet Metab. 2012;107(1–2):161—172.
   PubMed Web of Science ®Google Scholar
• Wang G, Mostafa NZ, Incani V, et al. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. J Biomed Mater Res A. 2012;100(3):684–693.
   PubMed Web of Science ®Google Scholar
• Kasugai S, Fujisawa R, Waki Y, et al. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res. 2000;15(5):936–943.
   PubMed Web of Science ®Google Scholar
• Xinluan W, Yuxiao L, Helena NH, et al. Systemic drug delivery systems for bone tissue regeneration- a mini review. Curr Pharm Des. 2015;21(12):1575–1583.
   PubMed Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli BZ, et al. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab. 2016;109(1):33–40.
   Web of Science ®Google Scholar
• Gurda BL, De Guilhem De Lataillade A, Bell P, et al. Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol Ther. 2016;24(2):206–216.
   PubMed Web of Science ®Google Scholar
• Ruzo A, Marco S, Garcia M, et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther. 2012;23(12):1237–1246.
   PubMed Web of Science ®Google Scholar
• Hinderer C, Bell P, Gurda BL, et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther. 2014;22(12):2018–2027.
   PubMed Web of Science ®Google Scholar
• Sorrentino NC, D’Orsi L, Sambri I, et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol Med. 2013;5(5):675–690.
   PubMed Web of Science ®Google Scholar
• Vance M, Llanga T, Bennett W, et al. AAV gene therapy for MPS1-associated corneal blindness. Sci Rep. 2016;6:22131.
   PubMed Web of Science ®Google Scholar
• Fein DE, Limberis MP, Maloney SF, et al. Cationic lipid formulations alter the in vivo tropism of AAV2/9 vector in lung. Mol Ther. 2009;17(12):2078–2087.
   PubMed Web of Science ®Google Scholar
• Carvalho TG, Silveira Matte U, Giugliani R, et al. Genome editing: potential treatment for lysosomal storage diseases. Curr Stem Cell Reports. 2015;1(1):9–15.
   Google Scholar
• Tan WS, Carlson DF, Walton MW, et al. Precision editing of large animal genomes. Adv Genet. 2012;80:37–97.
   PubMed Web of Science ®Google Scholar
• Esvelt KM, Wang HH. Genome-scale engineering for systems and synthetic biology. Mol Syst Biol. 2013;9:641.
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Bell JB, Khan SA, et al. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther. 2009;17(7):1136–1144.
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Hall BC, Bell JB, et al. Quantitative analysis of alpha-L-iduronidase expression in immunocompetent mice treated with the sleeping beauty transposon system. PLoS One. 2013;8(10):e78161.
   PubMed Web of Science ®Google Scholar
• Fraga M, Bruxel F, Lagranha VL, et al. Influence of phospholipid composition on cationic emulsions/DNA complexes: physicochemical properties, cytotoxicity, and transfection on Hep G2 cells. Int J Nanomedicine. 2011;6:2213–2220.
   PubMed Web of Science ®Google Scholar